ArticleScientific reports2025
KCNQ4 c.546C>G variant is associated with early-onset high-frequency hearing loss, tinnitus, and cardiovascular comorbidities in Taiwanese adults.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
KCNQ4 encodes a voltage-gated potassium channel essential for ion balance and membrane potential regulation in inner ear hair cells. Mutations in KCNQ4 are associated with late-onset, high-frequency hearing loss that progressively worsens. This study aimed to compare carriers of the KCNQ4 c.546C>G variant with non-carriers to examine the relationship between this mutation and hearing loss, tinnitus, and cardiovascular diseases. This case-control study used data from the Taiwan Precision Medicine Initiative (TPMI) at Taichung Veterans General Hospital. A total of 95 KCNQ4 c.546C>G carriers and 95 non-carriers were recalled between August 2022 and June 2023. Participants underwent pure-tone audiometry, completed the Tinnitus Handicap Inventory (THI), and provided medical histories. Chi-square and Fisher's exact tests were used to compare categorical variables, and logistic regression assessed associations between various factors, THI scores, and hearing loss. The KCNQ4 carrier group showed significant hearing loss at 4 kHz (21.3 ± 16.1 dB) and 8 kHz (26.4 ± 21.6 dB), with greater severity at higher frequencies. The proportion of hearing loss was highest at 8 kHz (49.5%), followed by 4 kHz (33.7%) and 2 kHz (21.1%). THI scores and incidence of cardiovascular diseases were also significantly higher among carriers. Factors affecting mid- and high-frequency hearing loss included the KCNQ4 variant (odds ratio [OR], 2.07) and age (OR, 1.12). After adjusting for cardiovascular disease, carriers still exhibited significant hearing loss at 4 kHz and 8 kHz. Carriers younger than 40 years had a higher risk of hearing loss at 8 kHz (OR, 4.89). Genetic testing for the KCNQ4 c.546C>G variant and annual audiometric evaluations are strongly recommended for patients under 40 years old with high-frequency hearing loss, tinnitus, and cardiovascular comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.